Campbell & Co Investment Adviser’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.21M | Buy |
13,309
+6,875
| +107% | +$3.87M | 0.38% | 27 |
|
|
2026
Q1 | $3.82M | Buy |
+6,434
| New | +$3.2M | 0.22% | 125 |
|
|
2025
Q3 | – | Sell |
-4,140
| Closed | -$1.19M | – | 1398 |
|
|
2025
Q2 | $1.19M | Sell |
4,140
-3,362
| -45% | -$1M | 0.08% | 429 |
|
|
2025
Q1 | $2.31M | Buy |
+7,502
| New | +$2.57M | 0.18% | 154 |
|
|
2024
Q4 | – | Sell |
-1,043
| Closed | -$374K | – | 1389 |
|
|
2024
Q3 | $374K | Buy |
+1,043
| New | +$352K | 0.03% | 825 |
|
|
2024
Q2 | – | Sell |
-5,932
| Closed | -$1.36M | – | 1365 |
|
|
2024
Q1 | $1.36M | Sell |
5,932
-2,313
| -28% | -$522K | 0.12% | 269 |
|
|
2023
Q4 | $1.81M | Buy |
8,245
+5,120
| +164% | +$1.18M | 0.16% | 164 |
|
|
2023
Q3 | $706K | Buy |
3,125
+1,678
| +116% | +$386K | 0.08% | 390 |
|
|
2023
Q2 | $319K | Sell |
1,447
-9,071
| -86% | -$2.01M | 0.06% | 633 |
|
|
2023
Q1 | $2.36M | Buy |
10,518
+3,974
| +61% | +$980K | 0.44% | 12 |
|
|
2022
Q4 | $1.82M | Buy |
+6,544
| New | +$1.65M | 0.44% | 12 |
|
|
2022
Q3 | – | Sell |
-7,835
| Closed | -$1.85M | – | 951 |
|
|
2022
Q2 | $1.85M | Buy |
7,835
+6,127
| +359% | +$1.25M | 0.5% | 16 |
|
|
2022
Q1 | $306K | Buy |
1,708
+366
| +27% | +$69.7K | 0.08% | 473 |
|
|
2021
Q4 | $290K | Sell |
1,342
-1,500
| -53% | -$294K | 0.1% | 370 |
|
|
2021
Q3 | $525K | Buy |
+2,842
| New | +$560K | 0.17% | 200 |
|
|
2021
Q2 | – | Sell |
-1,292
| Closed | -$216K | – | 724 |
|
|
2021
Q1 | $216K | Sell |
1,292
-418
| -24% | -$69.7K | 0.13% | 335 |
|
|
2020
Q4 | $260K | Sell |
1,710
-600
| -26% | -$78.7K | 0.16% | 280 |
|
|
2020
Q3 | $233K | Sell |
2,310
-2,355
| -50% | -$258K | 0.17% | 269 |
|
|
2020
Q2 | $564K | Buy |
+4,665
| New | +$525K | 0.71% | 14 |
|
|
2018
Q4 | – | Sell |
-1,794
| Closed | -$229K | – | 514 |
|
|
2018
Q3 | $229K | Buy |
+1,794
| New | +$222K | 0.16% | 304 |
|
|
2017
Q2 | – | Sell |
-1,504
| Closed | -$204K | – | 373 |
|
|
2017
Q1 | $204K | Buy |
+1,504
| New | +$228K | 0.53% | 108 |
|
|
2014
Q3 | – | Sell |
-16,907
| Closed | -$1.5M | – | 254 |
|
|
2014
Q2 | $1.5M | Buy |
+16,907
| New | +$1.63M | 0.6% | 71 |
|
|
2014
Q1 | – | Sell |
-6,900
| Closed | -$780K | – | 304 |
|
|
2013
Q4 | $780K | Buy |
+6,900
| New | +$622K | 0.18% | 138 |
|
Other funds holding UTHR
ACA
JT
Campbell & Co Investment Adviser's UTHR Position: Q2 2026 in Review
Campbell & Co Investment Adviser increased its United Therapeutics (UTHR) stake by 107% in Q2 2026, buying an estimated $3.87M and bringing the position to 13,309 shares worth $7.21M. The position accounts for 0.38% of the portfolio, ranked #27.
Campbell & Co Investment Adviser first reported a position in UTHR in Q4 2013 and has held it in 23 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Campbell & Co Investment Adviser held 13,309 shares of United Therapeutics worth $7.21M as of Q2 2026.
- Campbell & Co Investment Adviser bought 6,875 United Therapeutics shares in Q2 2026, an estimated $3.87M.
- United Therapeutics made up 0.38% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #27 holding.
- Campbell & Co Investment Adviser first reported a position in United Therapeutics in Q4 2013 and has held it in 23 quarters since.
- 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.